ClinicalTrials.gg
Not yet recruitingNCT07685197Updated Jul 6, 2026

Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC

A Phase 2 interventional study of receive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection in NSCLC, EGFR Activating Mutation and EGFR-TKI-resistant Non-Small Cell Lung Cancer, sponsored by Zhou Chengzhi. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Zhou Chengzhi · Phase 2, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective is to evaluate the correlation between ⁶⁸Ga-MY6349 PET/CT-derived metrics reflecting tumoral TROP2 expression activity (including SUVmax, SUVmean, MTV, TLG, etc.) and progression-free survival (PFS) assessed per RECIST v1.1. This study plans to enroll 100 EGFR-mutant patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance following first-line therapy with third-generation EGFR-TKIs.

Screening assessments will be completed within 28 days after patients sign the informed consent form. Eligible subjects will undergo a baseline ⁶⁸Ga-MY6349 PET/CT scan prior to study drug administration, with imaging coverage from mid-thighs to the vertex of the skull. All subjects will receive a ¹⁸F-FDG PET/CT scan within 14 days after the ⁶⁸Ga-MY6349 PET/CT. For patients who have undergone ¹⁸F-FDG PET/CT within 14 days before the ⁶⁸Ga-MY6349 scan, the existing imaging data can be used for diagnostic performance evaluation, and repeat ¹⁸F-FDG PET/CT is not required.

Subsequently, subjects will receive monotherapy with sacituzumab govitecan at a dose of 5 mg/kg via intravenous infusion (IV) on Day 1 of each cycle, administered every 2 weeks (Q2W). Treatment will continue until investigator-confirmed radiological disease progression, intolerable adverse toxicity, voluntary treatment discontinuation by the subject, or any other protocol-specified treatment discontinuation criterion, whichever occurs first.

At 3 months after initiation of sacituzumab govitecan treatment, subjects will repeat the ⁶⁸Ga-MY6349 PET/CT scan (coverage: mid-thighs to vertex), followed by a ¹⁸F-FDG PET/CT examination within 14 days thereafter.

Eligible subjects will receive regular tumor assessments in accordance with RECIST v1.1. Within 48 weeks after the first dose, imaging-based tumor assessments will be performed every 6 weeks (±7 days). At Week 12 (±1 week), paired ⁶⁸Ga-MY6349 and ¹⁸F-FDG PET/CT scans will be conducted without routine diagnostic CT. After Week 48, tumor assessments will be scheduled every 12 weeks (±7 days) until radiological disease progression, initiation of subsequent anti-tumor therapy, withdrawal of informed consent, loss to follow-up, death, or study termination by the sponsor, whichever comes first. Imaging assessments will follow the predetermined schedule regardless of dose delays or dose modifications.

After the first documented complete response (CR) or partial response (PR), response confirmation imaging must be conducted no less than 4 weeks (28 days) later. For subjects discontinuing treatment for reasons other than radiological progression, death or loss to follow-up, if more than 4 weeks have passed since the last imaging evaluation, repeat imaging will be performed at the End-of-Treatment (EOT) visit. Subsequent imaging assessments will be conducted per schedule to the greatest extent feasible until radiological disease progression, initiation of new anti-tumor therapy, consent withdrawal, loss to follow-up, death, or sponsor-initiated study termination, whichever occurs earliest.

All ⁶⁸Ga-MY6349 PET/CT images will be blindly and independently reviewed by two experienced nuclear medicine physicians who are not involved in this clinical trial (without access to any clinical data) to identify positive NSCLC lesions, as well as lesion location and count. In case of disagreement between the two independent readers regarding the presence of positive lesions, a blinded arbitration review by a senior nuclear medicine expert will be activated, and the arbitrator's reading results will serve as the final conclusion. All ¹⁸F-FDG PET/CT images will undergo single blinded independent review by one nuclear medicine physician.

Upon completion of treatment, all subjects will complete safety follow-up regardless of whether they receive subsequent anti-tumor therapy. Telephone-based survival follow-up visits will be conducted every 3 months (±14 days) after the last dose of study treatment to collect survival status and information on subsequent anti-tumor treatments, until subject withdrawal, loss to follow-up, death, or study closure, whichever occurs first.

02

Conditions studied

  • NSCLC
  • EGFR Activating Mutation
  • EGFR-TKI-resistant Non-Small Cell Lung Cancer
  • Trop2
  • PET/CT Imaging
03

In context

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's planned enrollment of 100 is above the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Zhou Chengzhi is the lead sponsor of 14 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years at the time of signing the form, with no restriction on gender.
  • or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC), classified as locally advanced Stage IIIB/IIIC or Stage IV NSCLC (per the 8th edition of UICC/AJCC TNM staging system for lung cancer), and not eligible for curative resection and/or definitive radiotherapy (with or without concurrent chemotherapy).
  • Presence of EGFR sensitizing mutations (exon 19 deletion or exon 21 L858R point mutation).
  • Subjects who have received third-generation EGFR-TKI therapy with documented treatment failure. For subjects previously treated with third-generation EGFR-TKIs in adjuvant, or consolidation settings, such TKI therapy will be regarded as first-line treatment for locally advanced or metastatic disease if disease progression occurs within ≤6 months after the last dose.
  • At least one as defined by v1.1; previously irradiated lesions shall not be selected as target lesions. Subjects with only cutaneous or osseous lesions are not eligible for enrollment.
  • (ECOG) performance status of 0 or 1 within 7 days prior to study drug administration.
  • Estimated ≥12 weeks.
  • Adequate organ and bone marrow function (no blood transfusion, recombinant thrombopoietin or colony-stimulating factor administered within 2 weeks before dosing), defined as follows:

    1. Hematology: (NEUT#) ≥1.5×10⁹/L; (PLT) ≥100×10⁹/L; ≥90 g/L.
    2. Hepatic function: (AST) and alanine aminotransferase (ALT) ≤2.5×; total (TBIL) ≤1.5×ULN; albumin ≥30 g/L. For subjects with hepatic metastases at baseline, ALT and AST ≤5×ULN, TBIL ≤3×ULN.
    3. Renal function: ≥50 mL/min (calculated using the standard Cockcroft-Gault formula).
    4. Coagulation function: (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤1.5×ULN.
  • Females of and male subjects whose partners are of childbearing potential must agree to use effective medical from the date of informed consent signature through 6 months after the last study drug administration.
  • The subject voluntarily participates in this study, signs the informed consent form, and is able to comply with all protocol-specified visits and relevant procedures.

Exclusion criteria

Exclusion Criteria:

  • Tumor histology or cytology confirms mixed components including small cell lung cancer, neuroendocrine carcinoma, carcinosarcoma, or squamous cell carcinoma.
  • Subjects with known , brainstem , spinal cord metastases/compression, or symptomatic unstable central nervous system (CNS) metastases are excluded unless they are off therapy and maintain stable neurological status for at least two weeks after completion of definitive radiotherapy and steroid tapering.
  • Prior systemic anti-tumor therapy for locally advanced or metastatic non-squamous NSCLC other than third-generation EGFR-TKIs (e.g., chemotherapy, immunotherapy).
  • Previous treatment with any TROP2-targeted agents or therapeutics containing topoisomerase I inhibitors, including antibody-drug conjugates (ADCs), whether administered in adjuvant, , or metastatic disease settings.
  • Thoracic radiotherapy with a cumulative dose >30 Gy delivered within 6 months prior to the first dose; non-thoracic or extended-field radiotherapy with a cumulative dose >30 Gy administered within 4 weeks prior to the first dose. Palliative radiotherapy for symptom control is permitted only if completed at least 2 weeks before study drug initiation.
  • History of another primary malignant tumor within 3 years before the first dose, excluding cured by local therapy such as basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, and cervical carcinoma in situ.
  • Presence of any of the following cardiovascular or cerebrovascular diseases or risk factors:

    1. Myocardial infarction, unstable angina, acute or persistent myocardial ischemia, (NYHA) Class III/IV heart failure, symptomatic or poorly controlled severe arrhythmia, cerebrovascular accident, , or other severe cardiovascular/cerebrovascular events within 6 months before dosing.
    2. Medical history of myocarditis, primary cardiomyopathy, or specific cardiomyopathies.
    3. Deep vein thrombosis, peripheral arterial thromboembolism, pulmonary embolism, or other severe thromboembolic events within 3 months prior to dosing (subjects may be enrolled if stably treated with low-molecular-weight heparin or equivalent anticoagulants for ≥2 weeks).
    4. Life-threatening major vascular diseases including aortic aneurysm or aortic dissection requiring surgical intervention within 6 months before dosing.
    5. interval (QTcF) >470 ms.
  • Uncontrolled systemic diseases as judged by the investigator:

    1. Poorly controlled diabetes mellitus (two consecutive fasting blood glucose readings ≥10 mmol/L).
    2. Uncontrolled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg).
    3. Clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once per week.
  • History of steroid-dependent non-infectious interstitial lung disease (ILD) or non-infectious pneumonitis; active ILD or non-infectious pneumonitis at screening; or suspicious ILD/pneumonitis that cannot be ruled out by screening imaging.
  • Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or history of severe corneal disorders that hinder or delay corneal wound healing.
  • severe pulmonary impairment secondary to concurrent lung disorders, including but not limited to underlying lung diseases (e.g., severe asthma, advanced , restrictive lung disease within 3 months prior to dosing); , connective tissue, or inflammatory disorders with pulmonary involvement (rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.); or prior pneumonectomy.
  • Active chronic inflammatory bowel disease, gastrointestinal obstruction, severe ulceration, gastrointestinal perforation, intra-abdominal abscess, or acute gastrointestinal hemorrhage.
  • Active gastrointestinal disorders or other conditions that substantially alter the absorption, distribution, metabolism, or excretion of oral study drugs (e.g., nausea and vomiting, chronic gastrointestinal disease, inability to swallow oral medication, history of extensive intestinal resection).
  • Risk of esophagotracheal or esophagopleural fistula; tumor invasion or compression of vital adjacent organs and vessels (heart, esophagus, superior vena cava, etc.) accompanied by relevant clinical manifestations such as superior vena cava syndrome.
  • Toxicities from prior anti-tumor therapy that have not resolved to Grade ≤1 per v5.0 or the thresholds specified in eligibility criteria (alopecia, fatigue, and other toxicities judged low-risk by the investigator are exempted).
  • Severe infection occurring within 4 weeks before dosing, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic antimicrobial therapy within 2 weeks before dosing.
  • Confirmed active pulmonary tuberculosis. Subjects with suspected active tuberculosis must undergo clinical examinations to rule out infection before enrollment.
  • Active (HBsAg-positive with HBV-DNA ≥500 IU/mL or above the lower limit of quantification, whichever is higher); active (anti-HCV positive with HCV-RNA above the lower limit of quantification); or concurrent HBV and HCV co-infection.
  • Positive (HIV) serology or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
  • History of allogeneic solid organ transplantation or hematopoietic stem cell transplantation.
  • Major surgery performed within 4 weeks prior to dosing or major surgery planned during study participation.
  • Known to the study drug or any of its (including polysorbate 20); history of severe hypersensitivity reactions to other biologic agents.
  • Non-specific immunomodulatory therapy (including but not limited to interferon, IL-2) or proprietary Chinese medicines with approved anti-tumor indications administered within 2 weeks before dosing.
  • Current use (or inability to discontinue prior to the first study dose) of drugs or herbal supplements that are strong cytochrome P450 (CYP) 3A4 inducers, with a minimum 3-week required. All subjects shall avoid concomitant use of any -inducing medications, herbal supplements, and/or relevant foods throughout the study.
  • administered within 30 days before dosing or planned live vaccination during study participation.
  • Rapid clinical deterioration during screening, such as marked decline in performance status.
  • Pregnant or breastfeeding women.
  • Local or systemic non-malignant diseases, or tumor-induced diseases/symptoms that carry high medical risks and/or cause uncertainty in survival assessment, such as leukemoid reaction, cachexia, etc.
  • Any medical condition that, in the investigator's opinion, may confound the evaluation of the study drug, compromise subject safety, interfere with the interpretation of study results, or render the subject unsuitable for trial participation.
Terms in these criteria, in plain language(39)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Diagnostic Test: receive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection

Interventions

  • Diagnostic testreceive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection

    All enrolled subjects shall receive treatment with TROP2-targeted ADC and undergo targeted molecular PET/CT imaging with ⁶⁸Ga-MY6349 injection at prespecified time points.

06

What researchers measure

Primary outcomes

  1. To evaluate the correlation between tumoral TROP2 expression activity detected by ⁶⁸Ga-MY6349 PET/CT and progression-free survival (PFS)

    Time frame: From study enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

Secondary outcomes

  1. To evaluate the correlation between tumoral TROP2 expression activity measured by ⁶⁸Ga-MY6349 and the following endpoints: Objective Response Rate, Duration of Response, Disease Control Rate, Overall Survival and safety outcomes.

    Time frame: From study enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  2. To evaluate the changes of ⁶⁸Ga-MY6349 PET quantitative parameters reflecting tumoral TROP2 expression activity from baseline to Month 3.

    Time frame: Baseline and Month 3

Other outcomes

  1. To evaluate the correlation between tumoral TROP2 expression activity quantified by ⁶⁸Ga-MY6349 and lung cancer biomarkers.

    Time frame: From study enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jul 2028, 24 months later.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 24 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jul 6, 2026
StartEst.
Jul 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07685197
Lead sponsor
Zhou Chengzhi
Collaborators
Guangzhou Institute of Respiratory Disease
Responsible party
Zhou Chengzhi (Professor, Guangzhou Institute of Respiratory Disease) — Sponsor-investigator
First posted
Jul 6, 2026
Start date
Jul 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jul 6, 2026

Study contacts

Wang Fei
Contact
2321699483@qq.com
18355293991

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion